Pages

Wednesday, November 19, 2014

Longer use of blood-thinning medications may benefit heart patients who have had a stent implanted.

The Wall Street Journal (11/17, Winslow, Subscription Publication) reports that research presented at an American Heart Association meeting and published online in the New England Journal of Medicine suggests that longer use of blood-thinning medications may be beneficial in heart patients who have had a stent implanted.

        Forbes (11/17) contributor Larry Husten writes that “after receiving a drug-eluting stent and one year of treatment with a thienopyridine and aspirin, 9,961 patients were randomized to 18 additional months of treatment with a thienopyridine or placebo.” Meanwhile, “both groups continued to take aspirin.”

        The AP (11/17, Marchione) reports that the researchers found that approximately “6 percent of those taking only aspirin suffered a heart attack, clot or other heart-related problem during that time versus about 4 percent of those taking a second drug.” The AP adds, “The FDA says it is mulling the results and that doctors should not change practice yet.”

Energy drinks may cause seizures, heart problems in young kids.

NBC Nightly News (11/16, story 7, 1:40, Holt) reported, “We’re back now with a new warning about the popular energy drinks and the potential danger they present when they get into the hands of young children.” NBC News medical contributor Natalie Azar, MD, explained, “Researchers looked at records from 55 poison control centers over a three-year period and found more than 5,000 cases of energy drink exposure,” nearly all of which were unintentional. Additionally, more “than 40 percent involved children under the age of six.”

        Bloomberg News (11/17, Cortez) reports that some of the children who drank energy drinks ended up “suffering seizures and heart problems.” Individuals “of all ages with underlying health conditions should be vigilant about the heavily caffeinated beverages...said” Steven Lipshultz, MD, chairman of pediatrics at Wayne State University in Detroit, MI. The study data were presented over the weekend at the American Heart Association conference.

        HealthDay (11/17, Doheny) reports, “Some energy drinks have up to 400 milligrams (mg) of caffeine per serving, Lipshultz said, compared to about 100 mg or 150 mg in” the average cup of coffee.

Level of Potassium Additives in Low-Sodium Meats May Be Unsafe for Patients with CKD

In an analysis of 19 sodium-reduced meat and poultry products from the main grocery store chains in Canada, the sodium-reduced products contained 25% to 55% less sodium than their non-sodium-reduced counterparts, but the potassium content of sodium-reduced products ranged from 210 to 1500 mg/100 g and was significantly higher than non-sodium-reduced products by 195 mg/100 g. Potassium-containing additives were found on the ingredient list in 63% of the sodium-reduced products and 25% of the non-sodium-reduced products. The amounts of phosphorus did not differ significantly between the 2 groups. The findings were presented at ASN Kidney Week 2014.

Studies cast doubt on benefits of milk consumption in adults

Aaron E. Carroll, MD, MS, professor of pediatrics at Indiana University School of Medicine, writes in the New York Times (11/18, Subscription Publication) “The Upshot” blog that an increasing amount of research now suggests that “milk consumption may not only be unhelpful, it might also be detrimental” in adults. This finding comes despite “the fact that the United States Department of Agriculture and other organizations advocate that even adults should drink at least three cups a day.” Studies have found that milk consumption during adolescence appears not to reduce the chance of fractured hips in senior years. In a Swedish study, milk consumption was tied to a greater risk for fractures in women and absolutely no protection at all against fractures in men. Dr. Carroll contends that even though milk has its place on cereal and as an accompaniment to cookies, “there’s very little evidence that most adults need it.”

Aspirin may not help prevent a first heart attack or stroke.

TIME (11/18, Park) reports that research published online in the Journal of the American Medical Association and presented at the American Heart Association annual meeting suggests that aspirin may not help prevent a first heart attack or stroke. The study included more than 14,600 “volunteers between the ages of 60 years and 85 years.” None of the “participants...had had any heart events, but” they all “had at least one of the risk factors that could make them vulnerable.”

        Forbes (11/17) contributor Larry Husten writes that the study “randomized...patients to aspirin 100 mg once daily or no aspirin in addition to conventional therapy.” Participants “were followed for up to 6.5 years for the primary combined endpoint of cardiovascular death, nonfatal stroke, or nonfatal MI.” Husten writes that “the independent Data Monitoring Committee discontinued the study after a smaller number than expected endpoints had occurred and it became clear the trial would not be able to reach a statistically significant result.”

        CardioSource (11/18) reports, “In both the aspirin and no aspirin groups, 56 fatal events occurred.” Participants “with an occurrence of nonfatal stroke totaled 114 in the aspirin group and 108 in the no aspirin group; of nonfatal myocardial infarction, 20 in the aspirin group and 38 in the no aspirin group; of undefined cerebrovascular events, three in the aspirin group and five in the no aspirin group.”

        MedPage Today (11/18, Phend) pointed out that “an exploratory analysis suggested a 28% probability that the trial would have been positive if it had continued for the full planned number of events instead of being terminated early for futility after a median 5.02 years of follow-up.” HealthDay (11/18, Thompson) also covers the story.

Study : nearly 30% of people with diabetes remain undiagnosed.

TIME (11/18, Worland) reports that a study published in the Annals of Internal Medicine “suggests that nearly 30% of adults with diabetes remain undiagnosed—the same rate as people with HIV.” The study also suggests that “just like many HIV patients, only about 20% of diabetes patients are treated satisfactorily.”

Medscape (11/18, Tucker) reports that the study found that “the majority of people with undiagnosed diabetes in the United States not only have a usual healthcare provider but have made two or more visits in the past year.”

Adding Ezetimibe To Statin Therapy May Reduce CV Events In High-Risk Patients With ACS.

On the CBS Evening News (11/17, story 7, 1:50, Pelley) , CBS’ Dr. Jon Lapook reported that a study presented at a meeting of the American Heart Association “may change the way” physicians “treat patients with heart attacks or severe chest pain.”

The New York Times (11/18, Kolata, Subscription Publication) reports that “the six-year study...involved 18,000 people who had had heart attacks or episodes of chest pain so severe they went to a hospital.” Participants “were randomly assigned to take” simvastatin or Vytorin (ezetimibe and simvastatin). Investigators found that “there were 6.4 percent fewer cardiac events — heart disease deaths, heart attacks, strokes, bypass surgeries, stent insertions and hospitalizations for severe chest pain — in those assigned to take Vytorin.”

USA Today (11/18, Weintraub) reports that participants given Vytorin “had an average LDL cholesterol of 54 mg/dL, compared with 69 mg/dL for those treated with just the statin.” Study leader Dr. Christopher Cannon “said the study shows that patients and doctors need to continue focusing on lowering cholesterol.” USA Today adds that the study is “the first to show that a different type of cholesterol-lowering drug can improve upon statins.” Dr. Patrick O’Gara, president of the American College of Cardiology, said, “The past is littered with trials that adding anything to statins is not effective.”

The AP (11/18, Marchione) reports that the data indicated that “for every 56 people taking Vytorin for seven years, one additional heart attack, stroke or heart-related death would be prevented.”

The Washington Post (11/17, Cha) “To Your Health” blog reports that “Merck says it plans to submit the data to the Food and Drug Administration in mid-2015 to get approval to market the drug for reducing major cardiovascular events.”

On its website, CBS News (11/18, LaPook) points out that “one year ago, new cardiology guidelines from the American Heart Association and the American College of Cardiology suggested” physicians “stop targeting specific LDL levels because there was no good evidence one low level was better than another.”

In Forbes (11/17), Matthew Herper writes, “At the heart of the Vytorin story is a big scientific question: how much can we trust that lowering the bad cholesterol, known as low-density lipoprotein, or LDL, means preventing heart attacks.” While this research “won’t completely settle this issue...it does mean that scientists and doctors will assume that cutting LDL means preventing heart attacks and strokes.” Also covering the story are the NPR (11/18, Hensley) “Shots” blog, Reuters (11/18, Berkrot), Modern Healthcare (11/18, Rice, Subscription Publication), the Boston Globe (11/18, Kotz) “Daily Dose” blog, Bloomberg News (11/17, Cortez), MedPage Today (11/18, Peck), Medscape (11/18, O'Riordan), HealthDay (11/18, Thompson), the Wall Street Journal (11/18, Winslow, Subscription Publication), and the Wall Street Journal (11/17, Silverman) “Pharmalot” blog.